Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 2(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06015542Phase 2Recruiting

Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

Role: lead

NCT05620238Recruiting

Home Treatment With Carfilzomib in Patients With Multiple Myeloma

Role: lead

NCT05306587Completed

Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.

Role: lead

NCT04028115Phase 2Completed

Bone Healing During Ninlaro Exposure

Role: lead

NCT05724966Completed

Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma

Role: lead

NCT02286830Phase 4Completed

Prolonged Protection From Bone Disease in Multiple Myeloma

Role: lead

All 6 trials loaded